PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Advances Controlled Synthesis of Scorpion Venom Peptides for Brain Therapies
PreveCeutical’s ‘Nature Identical™’ efforts aim to create consistently reproducible versions of found-in-nature therapeutics Company has begun engineering redesign phase of select identified peptides derived from famed scorpion venom Preventative therapeutics market expected to generate $196.9 billion in revenues by 2024, demonstrating alternative health products’ potential PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) efforts to develop a synthesized and consistently reproducible ‘Nature Identical™’ scorpion venom, popular as a pain reliever and cancer therapy, has taken a new step toward marketability as the company commences work on re-engineering venom peptide components to stabilize them. The biotech company based in British…